Showing results (1401-1410 of 8,142) with videos related to

Sort By:
Pageof 815
Haematologica|December 5, 2015
Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activationHuiyong Chen, Tenzin Choesang, Huihui Li, et al.
Haematologica|October 3, 2015
Red blood cell alloimmunization is influenced by the delay between Toll-like receptor agonist injection and transfusionRahma Elayeb, Marie Tamagne, Philippe Bierling, et al.
Haematologica|November 19, 2013
Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemiaAlmut Bokemeyer, Cornelia Eckert, Franziska Meyr, et al.
Haematologica|November 19, 2013
Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpuraSilvia Ferrari, Kristina Palavra, Bernadette Gruber, et al.
Haematologica|November 19, 2013
The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trialLucas T van Eijk, Suzanne Heemskerk, Rob W van der Pluijm, et al.
Haematologica|October 22, 2013
Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II studyRoland B Walter, Bruno C Medeiros, Kelda M Gardner, et al.
Haematologica|October 22, 2013
The synergism of MCL1 and glycolysis on pediatric acute lymphoblastic leukemia cell survival and prednisolone resistanceIngrid M Ariës, Bo R Hansen, Troels Koch, et al.
Haematologica|March 1, 1989
In vitro growth of bone marrow-derived multipotent and lineage-restricted hematopoietic progenitor cells in myelodysplastic syndromesC Carlo-Stella, M Cazzola, P Bernasconi, et al.
Haematologica|September 2, 2014
Survival analysis in hematologic malignancies: recommendations for cliniciansJulio Delgado, Arturo Pereira, Neus Villamor, et al.
Haematologica|August 24, 2014
Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphomaThomas E Witzig, Michael B Tomblyn, Jamal G Misleh, et al.
Pageof 815